Inclusion Criteria:

1. Age > 18 years old, males or females;

2. Untreated patients with advanced melanoma confirmed by histopathology or cytology;

3. With tumor foci that can be evaluated by CT or MRI; at least one diameter ≥ 1 cm
(including metastatic lymph nodes, diameter ≥ 1 cm confirmed by CT scan); or
superficial focus ≥ 2 cm (confirmed by photos with calibration);

4. No contraindication for chemotherapy, with normal peripheral hemogram, renal and
hepatic function: Peripheral hemogram: WBC≥4.0×109/L，PLT≥80×109/L，Hgb≥90g/L； Renal
function: serum BUN and creatinine ≤2.5×UNL; Hepatic function: transaminase≤2.5×UNL,
or ≤5×UNL in patients with liver metastasis;

5. Karnofsky performance scale≥70 (appendix 1); expected survival time≥3 months;

6. Patients are voluntary to participate and sign the informed contents.

Exclusion Criteria:

1. Pregnant or breast-feeding females; or females who have reproductive ability but do
not take contraception method;

2. With severe acute infection uncontrolled; purulent or chronic infection with wounds
difficult to recover;

3. With history of severe heart diseases, including congestive heart failure,
uncontrolled arrhythmia with high risk, unstable angina pectoris, myocardial
infarction, severe cardiac valvular diseases and refractory hypertension;

4. Have been treated by dacarbazine or dacarbazine included combination chemotherapy;

5. Patients with uncontrolled neurological, mental disease or psychosis, patients with
poor compliance that cannot coordinate the therapy or describe the treatment
response;

6. Uncontrolled brain metastasis patients with obvious manifestations of intracranial
hypertension or neurological and mental disorders;

7. Allergic to any drug in the trial;

8. Patients with a second tumor;

9. Patients participating in other clinical trials;

10. Other conditions that are regarded for exclusion by the trialists